Previous 10 | Next 10 |
Synlogic, Inc. (SYBX) Q2 2019 Earnings Conference Call August 8, 2019 5:00 PM ET Company Participants Elizabeth Wolffe – Head-Investor Relations Aoife Brennan – President and Chief Executive Officer Todd Shegog – Chief Financial Officer Scott Plevy –...
The following slide deck was published by Synlogic, Inc. in conjunction with this Read more ...
Synlogic, Inc. (NASDAQ: SYBX) announced today that Scott Plevy, M.D., Synlogic’s chief scientific officer, will provide a corporate update at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13 at 9:45 am ET, in New York City. A live webcast of the pr...
Synlogic (NASDAQ: SYBX ): Q2 GAAP EPS of -$0.45 beats by $0.04 . More news on: Synlogic, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Strong balance sheet supports clinical advancement of lead and emerging Synthetic Biotic ™ programs – –Bridging study to evaluate solid oral formulation of SYNB1618 open and recruiting healthy volunteers – – Company will host a conferen...
Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its second quarter 2019 financial results after the market closes on Thursday, August 8, 2019. The pr...
Thinly traded micro cap Synlogic ( SYBX +5.9% ) is up on modestly higher volume in reaction to positive topline data from a Phase 1/2a clinical trial evaluating SYNB1618 in patients with an inborn error of metabolism called phenylketonuria (PKU) characterized by decreased metabolism of...
– Data demonstrate statistically significant biomarker activity at well-tolerated dose in PKU patients – – Plan to initiate bridging study with new oral solid formulation in Q3 2019 – – Conference call and webcast today, July 15, at 8:00 a.m. ET ...
SYBX stock is making solid movement after Synlogic Inc (NASDAQ:SYBX) announced an $80 million equity investment from Ginkgo Bioworks. Ginkgo’s Investment is Key for Synlogic As one of the leading biopharmaceutical companies, Synlogic Inc (SYBX) makes use of synthetic biology to g...
Gainers: Synlogic (NASDAQ: SYBX ) +28% . Immuron (NASDAQ: IMRN ) +26% . B Communications (NASDAQ: BCOM ) +23% . Arcadia Biosciences (NASDAQ: RKDA ) +17% . Vuzix Corporation (NASDAQ: VUZI ) +14% . MagnaChip Semiconductor Corporation (NYSE: MX ) +13% . Osmotica Pharmaceuticals (N...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023. The Company...
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the “Board”) has approved the adoption of a limited dur...
A look at the top 10 most actives in the United States NanoString Technologies Inc. (NSTG) rose 97.9% to $0.23 on volume of 419,200,402 shares Sunworks Inc. (SUNW) rose 87.9% to $0.1022 on volume of 385,386,904 shares Green Giant Inc. (GGE) rose 15.4% to $0.0427 on volume of 208,454,257 s...